


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

| | |
|-------------------|----------------------------------|
| USAN | AVAGACESTAT |
| PRONUNCIATION | a" va gay' se stat |
| THERAPEUTIC CLAIM | Treatment of Alzheimer's disease |

CHEMICAL NAMES

1. Pentanamide, 2-[[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoro-, (2*R*)-
2. (2*R*)-2-([(4-chlorophenyl)sulfonyl]{[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl}amino)-5,5,5-trifluoropentanamide
3. *N*²-((4-Chlorophenyl)sulfonyl)-5,5,5-trifluoro-*N*²-((2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl)methyl)-D-norvalinamide

STRUCTURAL FORMULA



| | |
|----------------------------|--|
| MOLECULAR FORMULA | C ₂₀ H ₁₇ ClF ₄ N ₄ O ₄ S |
| MOLECULAR WEIGHT | 520.88 |
| TRADEMARK | None as yet |
| SPONSOR | Bristol-Myers Squibb |
| CODE DESIGNATION | BMS-708163-01 |
| <u>CAS</u> REGISTRY NUMBER | 1146699-66-2 |